JP2008505148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008505148A5 JP2008505148A5 JP2007519697A JP2007519697A JP2008505148A5 JP 2008505148 A5 JP2008505148 A5 JP 2008505148A5 JP 2007519697 A JP2007519697 A JP 2007519697A JP 2007519697 A JP2007519697 A JP 2007519697A JP 2008505148 A5 JP2008505148 A5 JP 2008505148A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- nhl
- composition according
- chemotherapeutic regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 230000000973 chemotherapeutic effect Effects 0.000 claims 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 8
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical group CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- NYNAFINLHQEHKU-UHFFFAOYSA-N methyl 1-(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}benzoyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C(=O)C(C=C1)=CC=C1NCC1=CN=C(N=C(N)N=C2N)C2=N1 NYNAFINLHQEHKU-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58641404P | 2004-07-09 | 2004-07-09 | |
| PCT/EP2005/007213 WO2006005477A1 (en) | 2004-07-09 | 2005-07-07 | Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014006916A Division JP6034314B2 (ja) | 2004-07-09 | 2014-01-17 | Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008505148A JP2008505148A (ja) | 2008-02-21 |
| JP2008505148A5 true JP2008505148A5 (https=) | 2012-01-26 |
Family
ID=34972426
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007519697A Withdrawn JP2008505148A (ja) | 2004-07-09 | 2005-07-07 | Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療 |
| JP2014006916A Expired - Lifetime JP6034314B2 (ja) | 2004-07-09 | 2014-01-17 | Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014006916A Expired - Lifetime JP6034314B2 (ja) | 2004-07-09 | 2014-01-17 | Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20060029543A1 (https=) |
| EP (1) | EP1765399A1 (https=) |
| JP (2) | JP2008505148A (https=) |
| KR (1) | KR101250127B1 (https=) |
| AU (1) | AU2005261923B2 (https=) |
| BR (1) | BRPI0513007A (https=) |
| CA (1) | CA2568526C (https=) |
| IL (1) | IL179636A (https=) |
| MX (1) | MX2007000327A (https=) |
| NO (1) | NO344366B1 (https=) |
| RU (1) | RU2394596C2 (https=) |
| WO (1) | WO2006005477A1 (https=) |
| ZA (1) | ZA200701158B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8061104B2 (en) | 2005-05-20 | 2011-11-22 | Valinge Innovation Ab | Mechanical locking system for floor panels |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| KR20130009760A (ko) | 2010-02-10 | 2013-01-23 | 이뮤노젠 아이엔씨 | Ｃｄ２０ 항체 및 이의 용도 |
| US11055552B2 (en) * | 2016-01-12 | 2021-07-06 | Disney Enterprises, Inc. | Systems and methods for detecting light signatures and performing actions in response thereto |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7744877B2 (en) * | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| DK0752248T3 (da) * | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| PT1974747E (pt) * | 1998-08-11 | 2012-09-05 | Biogen Idec Inc | Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20 |
| WO2000059473A1 (en) * | 1999-04-01 | 2000-10-12 | Inex Pharmaceuticals Corp. | Compositions and methods for treating lymphoma |
| WO2001074388A1 (en) * | 2000-03-31 | 2001-10-11 | Idec Pharmaceuticals Corporation | Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
| WO2003068821A2 (en) * | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| EP1567863A4 (en) | 2002-11-22 | 2007-10-03 | Nuvelo Inc | THERAPY AND DIAGNOSTIC PROCEDURES |
-
2005
- 2005-07-07 WO PCT/EP2005/007213 patent/WO2006005477A1/en not_active Ceased
- 2005-07-07 JP JP2007519697A patent/JP2008505148A/ja not_active Withdrawn
- 2005-07-07 KR KR1020077000190A patent/KR101250127B1/ko not_active Expired - Lifetime
- 2005-07-07 RU RU2007104839/14A patent/RU2394596C2/ru not_active IP Right Cessation
- 2005-07-07 EP EP05761149A patent/EP1765399A1/en not_active Withdrawn
- 2005-07-07 CA CA2568526A patent/CA2568526C/en not_active Expired - Lifetime
- 2005-07-07 MX MX2007000327A patent/MX2007000327A/es active IP Right Grant
- 2005-07-07 BR BRPI0513007-7A patent/BRPI0513007A/pt not_active Application Discontinuation
- 2005-07-07 AU AU2005261923A patent/AU2005261923B2/en not_active Expired
- 2005-07-08 US US11/176,671 patent/US20060029543A1/en not_active Abandoned
-
2006
- 2006-11-27 IL IL179636A patent/IL179636A/en active IP Right Grant
-
2007
- 2007-02-08 NO NO20070763A patent/NO344366B1/no unknown
- 2007-02-08 ZA ZA200701158A patent/ZA200701158B/xx unknown
-
2014
- 2014-01-17 JP JP2014006916A patent/JP6034314B2/ja not_active Expired - Lifetime
-
2018
- 2018-05-14 US US15/978,460 patent/US20190112383A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roberts et al. | Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL 2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD 20+ lymphoid malignancies | |
| JP2008519047A5 (https=) | ||
| RU2019107011A (ru) | Композиции апилимода и способы их применения | |
| JP2004512262A5 (https=) | ||
| JP2015212268A5 (https=) | ||
| CA2633594C (en) | Means and methods for the treatment of tumorous diseases | |
| JP2018193377A5 (https=) | ||
| NO332893B1 (no) | Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi | |
| JP2016536361A5 (https=) | ||
| JP2008505857A5 (https=) | ||
| JP2010285439A5 (https=) | ||
| JP2006504723A5 (https=) | ||
| JP2006504795A5 (https=) | ||
| KR960030940A (ko) | 개선된 백금 착체 | |
| JP2018503610A5 (https=) | ||
| JP2020524670A5 (https=) | ||
| JP2020533302A5 (https=) | ||
| DK1140198T3 (da) | Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad | |
| JP2006514116A5 (https=) | ||
| JP2020523384A5 (https=) | ||
| Tuscano et al. | Anti-CD22 ligand-blocking antibody HB22. 7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts | |
| CA2672839A1 (en) | Treatment of lung cancer with s-farnesylthiosalicylic acid and analogs thereof | |
| JP2008505148A5 (https=) | ||
| JP2018506533A5 (https=) | ||
| JP2016501208A5 (https=) |